Olga Rafikova, MD, PhD

Co-Founder

Dr. Rafikova has worked in the area of cardiovascular and pulmonary diseases for over 20 years. From 2015, Dr. Rafikova is an Assistant Professor at the Department of Medicine, the University of Arizona, leading a multidisciplinary research group. She is an inventor, translational researcher, precision medicine, and sex-oriented innovator.

Dr. Rafikova has research interests in sex-specific therapeutic approaches in pulmonary arterial hypertension (PAH), a deadly disease with no effective therapy.

By using a combination of multiple preclinical models and patient samples her research team investigates

1) the gender-specific changes in the redox profile as a biomarker or prognostic factor for pulmonary diseases;

2) gender-specific circulating inflammatory markers, and

3) metabolites that could serve as a fingerprint of an early stage of asymptomatic disorders.

Dr. Rafikova dedicates a lot of her effort to design and test the unique peptide-based therapeutics that, in contrast to the classical “small molecule” inhibitors, specifically attenuate the pathological, disease driven signaling without affecting the normal physiological function of the protein. She has five active patent applications aimed to treat different cardiovascular diseases.

Contact Me

Your email address will not be published. Required fields are marked *